Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease

Figure 2

Kaplan–Meier curves for the cumulative incidence of the primary endpoint (occurrence of major bleeding or clinically significant bleeding) in the edoxaban monotherapy group and combination therapy group.